Condition (MeSH)
Pituitary ACTH Hypersecretion
ClinicalTrials.gov lists 61 trials for Pituitary ACTH Hypersecretion or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
61 of the 61 trials are tagged with Pituitary ACTH Hypersecretion itself; the rest are tagged with a narrower condition beneath it.
When did Pituitary ACTH Hypersecretion trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 4 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 33 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pituitary ACTH Hypersecretion trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 12 |
| Phase 3 | 13 |
| Phase 4 | 4 |
| Not applicable | 7 |
| Observational | 20 |
How many Pituitary ACTH Hypersecretion trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 12 |
| Enrolling by invitation | 2 |
| Active, not recruiting | 4 |
| Completed | 27 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pituitary ACTH Hypersecretion trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Corcept Therapeutics | 8 |
| Novartis Pharmaceuticals | 8 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 3 |
| Cortendo AB | 2 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Pituitary ACTH Hypersecretion? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mifepristone | 4 |
| Relacorilant | 3 |
| Osilodrostat | 3 |
| Levoketoconazole | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pasireotide s.c. | 6 |
| Cabergoline Pill | 2 |
| MRI | 2 |
| LMWH/Rivaroxaban | 1 |
| Pasireotide sub-cutaneous | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pituitary ACTH Hypersecretion trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cholelithiasis | 33 | 6 |
| Hyperglycaemia | 23 | 6 |
| Adrenal insufficiency | 20 | 9 |
| Pituitary-dependent Cushing's syndrome | 19 | 5 |
| Cholecystitis acute | 16 | 7 |
Showing 5 of 10 adverse events.
Which publications cover Pituitary ACTH Hypersecretion? (74)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4. | European journal of endocrinology | 2025 | Yes |
| Genetic evaluation of pediatric pituitary adenomas and USP8-related genotype-phenotype correlations in Cushing's disease. | Pituitary | 2025 | Yes |
| Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs). | Pituitary | 2025 | Yes |
| Postoperative Initiation of Thromboprophylaxis in patients with Cushing's Disease (PIT-CD): a randomized controlled trial. | Trials | 2025 | Yes |
| Prospective Multicenter Evaluation of [<sup>11</sup>C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2025 | Yes |
Showing 5 of 74 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| ACTH-dependent Cushing syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| ACTH-dependent Cushing syndrome | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Cushing disease | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Cushing disease | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Cushing disease | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Cushing disease | 96253 | Exact | Orphadata Science knowledge files, Product 1 |
| Cushing disease | 96253 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.